A surge in patent infringement lawsuits by Celgene Corp. against generic drug makers catapulted a New Jersey federal court to the top tier of patent litigation venues for the month of June.
The Summit, N.J.-based pharmaceutical company filed 18 patent infringement lawsuits in the U.S. District Court for the District of New Jersey, which saw a total of 25 such cases filed last month, a Bloomberg Law data analysis shows. The court’s June patent docket more than doubled from May, when it had 12 new patent complaints.
New Jersey, home to many drug companies, is a battleground venue for disputes ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.